Novavax NVAX shares are trading higher after the CDC said trial participants in the company's PREVENT-19 Phase 3 clinical trial meet the criteria to be considered fully vaccinated two weeks after they have completed the vaccine series.
"Novavax commends the CDC for its continued support for COVID-19 clinical trial volunteers, with this update providing clarity and guidance for participants in our PREVENT-19 Phase 3 clinical trial," said Gregory M. Glenn, M.D., President of Research and Development, Novavax.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.
At last check, Novavax was trading 2.60% higher at $239.28 per share during Tuesday's session.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
